-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, C2tAOS6S2N0JepBvbtpds1x4R9zRngSzXjPDNFpXz+nXfn5uorsr3wdC+3OwmVkH sERL7X8ZsUgchQfzqgxbeg== 0001387131-11-000194.txt : 20110211 0001387131-11-000194.hdr.sgml : 20110211 20110211164940 ACCESSION NUMBER: 0001387131-11-000194 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110204 ITEM INFORMATION: Other Events FILED AS OF DATE: 20110211 DATE AS OF CHANGE: 20110211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tamir Biotechnology, Inc. CENTRAL INDEX KEY: 0000708717 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222369085 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-11088 FILM NUMBER: 11599986 BUSINESS ADDRESS: STREET 1: 300 ATRIUM DRIVE CITY: SOMERSET STATE: NJ ZIP: 08873 BUSINESS PHONE: 732-652-4525 MAIL ADDRESS: STREET 1: 300 ATRIUM DRIVE CITY: SOMERSET STATE: NJ ZIP: 08873 FORMER COMPANY: FORMER CONFORMED NAME: ALFACELL CORP DATE OF NAME CHANGE: 19920703 8-K 1 tamir-8k_0211.htm CURRENT REPORT tamir-8k_0211.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  February 4, 2011

Tamir Biotechnology, Inc.
(Exact name of registrant as specified in its charter)

0-11088
(Commission File Number)

Delaware
  
22-2369085
(State or other jurisdiction of incorporation)
  
(I.R.S. Employer Identification No.)


11 Deer Park Drive, Suite 204, Princeton Corporate Plaza, Monmouth Junction, NJ 08852
(Address of principal executive offices, with zip code)

(732) 823-1003
(Registrant's telephone number, including area code)

Not Applicable
 (Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 

Item 8.01 Other Events.

On February 4, 2011, Tamir Biotechnology, Inc. (the “Company”) decided to suspend its Phase II trial of Ranpirnase (Onconase®) in combination with carboplatinum regimens in patients suffering from non-small cell lung cancer who have reached maximum progression after receiving two cycles of Alimta plus Carboplatin.  Given the Company's limited resources and based upon the previously reported positive in vitro results, the Company will focus on the completion of in vivo studies for Dengue Fever, Yellow Fever, Cytomegalovirus (CMV), and Human Papillomavirus (HPV).  The Company continues to seek financing that will be required to allow it to continue pursuing the development of Ranpirnase.

 
 
 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


   
TAMIR BIOTECHNOLOGY, INC.
     
Date: February 11, 2011
  
By:
/s/ Charles Muniz
   
Name:
Charles Muniz
   
Title:
President, Chief Executive Officer and
Chief Financial Officer
-----END PRIVACY-ENHANCED MESSAGE-----